Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study...
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1...
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today...
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in...
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue...
Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease...
AI-Driven Risk Prediction for Breast, Prostate and Pancreatic CancersTOKYO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese Name:...
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,...
RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services...
Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of...
ADDISON, Texas, Dec. 4, 2025 /PRNewswire/ -- HaloMD today announced the addition of three established executive experts across data, technology, and...
AUSTIN, Texas, Dec. 4, 2025 /PRNewswire/ -- PerfectQuote, Inc., the leading group health digital quoting and distribution platform, has announced...
Major Regulatory Milestone: The first Canadian-developed AI for ICH triage receives FDA clearance to enter the U.S. market.Operational Value: Automates...
Partnership Creates Synergy Between Both Companies in Advanced Technologies and Support Services for Drug DiscoveryMELVILLE, N.Y., Dec. 4, 2025 /PRNewswire/...
Powering the Cost Plus Marketplace for Businesses Through Transparency, Innovation and Trust NASHVILLE, TENNESSEE / ACCESS Newswire / December 4,...
A leader in medically supervised weight management, proudly announces a major milestone: more than 10 million pounds lost collectively by...
The U.S. healthcare revenue cycle is a multi billion-dollar problem plagued by inefficiency. MedEvolve CEO Matt Seefeld explains how generative...
MOUNTLAKE TERRACE, Wash., Dec. 4, 2025 /PRNewswire/ -- Premera Blue Cross, a leading not-for-profit health plan in the Pacific Northwest,...
